regulatory
confidence high
sentiment positive
materiality 0.60
EMA grants PRIME designation for Annexon's ANX007 in geographic atrophy
Annexon, Inc.
- PRIME designation based on Phase 2 ARCHER trial showing preservation of visual function.
- ANX007 is the first therapeutic candidate for GA to receive EMA PRIME designation.
- Company engaging with U.S. and EU regulators to design global Phase 3 program.
- Designation provides enhanced EMA support to expedite development and review.